Combined Treatment of Photodynamic Therapy and Bevacizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.
10.3341/kjo.2011.25.4.231
- Author:
Hyun Woong KIM
1
;
Jung Lim KIM
;
Mi Hyun LEE
;
Hyung Gon YOO
;
In Young CHUNG
;
Ji Eun LEE
Author Information
1. Department of Ophthalmology, Inje University College of Medicine, Busan, Korea.
- Publication Type:Original Article ; Comparative Study ; Research Support, Non-U.S. Gov't
- Keywords:
Bevacizumab;
Choroidal neovascularization;
Macular degeneration;
Photochemotherapy;
Verteporfin
- MeSH:
Aged;
Angiogenesis Inhibitors/*administration & dosage;
Antibodies, Monoclonal, Humanized/*administration & dosage;
Choroidal Neovascularization/diagnosis/*drug therapy/etiology;
Dose-Response Relationship, Drug;
Drug Therapy, Combination;
Female;
Fluorescein Angiography;
Follow-Up Studies;
Fundus Oculi;
Humans;
Intravitreal Injections;
Macula Lutea/drug effects/*pathology;
Macular Degeneration/*complications/diagnosis/drug therapy;
Male;
Photochemotherapy/*methods;
Photosensitizing Agents/administration & dosage;
Porphyrins/*administration & dosage;
Retrospective Studies;
Tomography, Optical Coherence;
Treatment Outcome;
Visual Acuity
- From:Korean Journal of Ophthalmology
2011;25(4):231-237
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To evaluate the outcome of a combined photodynamic therapy and intravitreal injection of bevacizumab in choroidal neovascularization secondary to age-related macular degeneration. METHODS: Photodynamic therapy (PDT) was administered to 28 eyes followed by 3 consecutive bevacizumab injections. Patients were followed-up for more than 12 months. At baseline, 1, 3, 6, and 12 months post PDT, visual acuity (VA) and central macular thickness were measured using optical coherence tomography. RESULTS: The mean VA was significantly improved from logarithm of the minimal angle of resolution 0.86 at baseline to 0.69 at 1 month (p = 0.011), 0.63 at 3 months (p = 0.003), 0.64 at 6 months (p = 0.004) and 0.60 at 12 months (p < 0.001). Central macular thickness decreased significantly from 328.3 microm at baseline to 230.0 microm at 6 months and 229.9 microm at 1 year (p < 0.001). Reinjection mean number was 0.4 for 6 months and 0.8 for 12 months. By 1 year, retreatment was performed in 10 eyes (36%). CONCLUSIONS: PDT combined with three consecutive intraviteal bevacizumab injections was effective in improving VA and reducing central macular thickness.
